Investors and Media

Press Releases

December 5, 2023
NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that a conference call and webcast will be held with executives from Arvinas and Pfizer Inc.
December 5, 2023
– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the potential of vepdegestrant in combination with palbociclib (IBRANCE ® ) – – Tolerability generally
November 27, 2023
NEW HAVEN, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has entered into a securities purchase agreement with a select group of institutional
November 2, 2023
NEW HAVEN, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in five upcoming investor conferences: Truist Securities
October 22, 2023
– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors harboring AR 878/875 mutations – – Interim data from the Phase 1/2 trial of Arvinas’ second PROTAC AR